

# Collaborations Pharmaceuticals, Inc., and Bausch + Lomb Bring Artificial Intelligence to Ocular Drug Discovery

*Collaborations Pharmaceuticals, Inc., and Bausch + Lomb Work Together to Bring Artificial Intelligence to Ocular Drug Discovery*

RALEIGH, NC, UNITED STATES, January 9, 2025 /EINPresswire.com/ --

[Collaborations Pharmaceuticals, Inc.](#)

(CPI) is pleased to announce a collaboration with [Bausch + Lomb](#) to leverage CPI's artificial intelligence (AI) machine learning tools and expertise to identify new drugs for eye diseases. Financial terms for this collaboration have not been disclosed.

Over the last year, CPI has been working with Bausch + Lomb on multiple preclinical and clinical drug discovery projects using its AI technologies. These include efforts to identify new drug candidates with ocular activity, drug distribution in the eye, transporters and models for the "eye-blood barrier", predictive models for clinical responses, as well as other projects. CPI has demonstrated multiple machine learning models to select molecules for further evaluation, streamlining the molecule repurposing and discovery process for ocular indications.

CPI is a privately held Raleigh-based company that has developed its own industry-leading AI software for drug discovery, toxicology and consumer product applications. Over the last four years, CPI has been building its generative AI capabilities and attracted global attention for its research. CPI is particularly noted for client work in ADME/Tox. It licenses its software and performs fee-for-service work for multibillion-dollar pharmaceutical, chemical and consumer product companies, in addition to developing its own drug discovery pipeline.

"We are honored to be working with Bausch + Lomb to bring AI to ocular research. By joining



**COLLABORATIONS  
PHARMACEUTICALS, INC.**

Collaborations Pharmaceuticals logo

forces with a leading eye health company with such a rich history, we are discovering new opportunities to demonstrate that our AI technologies can build on and expand the knowledge and understanding of what it takes to be a therapeutic for the eye. This is an example of where we can bring our expertise around data curation and machine learning to bear on an area that to date has not seen the application of AI. We look forward to a long and fruitful collaboration," commented Sean Ekins, PhD. CEO of CPI.

Sean Ekins

Collaborations Pharmaceuticals, Inc.

+1 215-687-1320

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/775558423>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.